Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.

At the GenScript Biotech Global Forum 2025, industry leaders celebrated CAR T cell therapy achievements while discussing ...

INmune Bio ( NASDAQ: INMB) announced a partnership with the Cell and Gene Therapy Catapult, a UK-based innovation center ...

Verve Therapeutics (NASDAQ:VERV) stock climbs as gene therapy shows promise in cutting LDL cholesterol by up to 69% in an early-stage trial. Read more here.

Gene therapies are a revolution in medicine but over the past few years, companies developing them for many serious ...

Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $40.1 billion by 2034, ...

Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

Listed below are links to the GEN stories reference in this episode of Touching Base Gene Therapy Tested in Mice Offers New Hope for People with Dravet Syndrome By Uduak Thomas, GEN, March 19, 2025 ...

On the heels of its acquisition by Ocuphire Pharma, Opus is planning next steps for its Leber congenital amaurosis type 5 ...

British racing is testing thoroughbreds for gene doping after investing almost £2m into ground-breaking research – and the ...